Afeyan Noubar 的 Form 4 申報
Moderna, Inc.（MRNA），2022/5/13 申報
- 申報編號
- 0000899243-22-018043
- 申報時間
- 2022/5/13
- 交易日
- 2022/5/11-5/13
- 申報延遲
- 2 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 9 筆非衍生性交易。公開市場賣出合計 $4,086 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Afeyan NoubarCIK 0001222012 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2022/5/11 | Common Stock | S賣出處分 | −10,000 | $130.74 | −$1,307,400 | 2,229,673 | 直接 | |
| 2022/5/12 | Common Stock | S賣出處分 | −75,944 | $129.39F2 | −$9,826,394.16 | 6,040,713 | 間接 | |
| 2022/5/12 | Common Stock | S賣出處分 | −41,182 | $130.08F4 | −$5,356,954.56 | 5,999,531 | 間接 | |
| 2022/5/12 | Common Stock | S賣出處分 | −51,256 | $131.45F5 | −$6,737,601.2 | 5,948,275 | 間接 | |
| 2022/5/12 | Common Stock | S賣出處分 | −31,618 | $132.22F6 | −$4,180,531.96 | 5,916,657 | 間接 | |
| 2022/5/13 | Common Stock | S賣出處分 | −25,433 | $133.11F7 | −$3,385,386.63 | 5,891,224 | 間接 | |
| 2022/5/13 | Common Stock | S賣出處分 | −24,567 | $134.04F8 | −$3,292,960.68 | 5,866,657 | 間接 | |
| 2022/5/13 | Common Stock | S賣出處分 | −49,900 | $135.37F9 | −$6,754,963 | 5,816,757 | 間接 | |
| 2022/5/13 | Common Stock | S賣出處分 | −100 | $136.00 | −$13,600 | 5,816,657 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
Represents (i) 63,512 shares sold by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and (ii) 12,432 shares sold by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.00 to $129.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,212,827 shares are held directly by Flagship Fund IV and 2,827,886 shares are held directly by Flagship Fund IV-Rx.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Represents (i) 34,589 shares sold by Flagship Fund IV and (ii) 6,593 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,178,238 shares are held directly by Flagship Fund IV and 2,821,293 shares are held directly by Flagship Fund IV-Rx.
表 I 有 1 筆交易的價格引用這則附註。
- F5
Represents (i) 43,035 shares sold by Flagship Fund IV and (ii) 8,221 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.00 to $131.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,135,203 shares are held directly by Flagship Fund IV and 2,813,072 shares are held directly by Flagship Fund IV-Rx.
表 I 有 1 筆交易的價格引用這則附註。
- F6
Represents (i) 26,546 shares sold by Flagship Fund IV and (ii) 5,072 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.00 to $132.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,108,657 shares are held directly by Flagship Fund IV and 2,808,000 shares are held directly by Flagship Fund IV-Rx.
表 I 有 1 筆交易的價格引用這則附註。
- F7
Represents (i) 21,250 shares sold by Flagship Fund IV and (ii) 4,183 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.00 to $133.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,087,407 shares are held directly by Flagship Fund IV and 2,803,817 shares are held directly by Flagship Fund IV-Rx.
表 I 有 1 筆交易的價格引用這則附註。
- F8
Represents (i) 20,621 shares sold by Flagship Fund IV and (ii) 3,946 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.00 to $134.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,066,786 shares are held directly by Flagship Fund IV and 2,799,871 shares are held directly by Flagship Fund IV-Rx.
表 I 有 1 筆交易的價格引用這則附註。
- F9
Represents (i) 41,885 shares sold by Flagship Fund IV and (ii) 8,015 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the reported transactions, 3,024,901 shares are held directly by Flagship Fund IV and 2,791,856 shares are held directly by Flagship Fund IV-Rx.
表 I 有 1 筆交易的價格引用這則附註。